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The physician from Greece, Aretaeus who coined the 
term ‘Diabetes’ said “life with Diabetes is short 
disgusting and painful’’.  
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The 21st century is the age of science, technology and 
computer, which is showing an unbalanced and faulty 
diet pattern and sedentary lifestyle. In studies 
conducted by ICMR – INDIA it shows that a large 
percentage of people in India are inactive with fewer 
than 10% engaging in recreational physical activity. 
Hence, showing an upward trend of lifestyle disorders 
in India at present. This has led to a drastic increase in 
several health problems, especially non-
communicable diseases among which Diabetes 
Mellitus (D.M) tops the list and has become a global 
public health concern.  
The features of Madhumeha mentioned in Ayurvedic 
Granthas can be correlated to D.M. A detail 
explanation of various Nidanas are coined which also 
show similarity like diet including Gramya, Udaka, 
A B S T R A C T  
Background: Non-communicable diseases are posing major health and development threats. The Worldwide, 
approximately 200 million people currently have type 2 DM, a prevalence that has been predicted to increase to 
366 million by 2030. Diabetes Mellitus comprises a group of common metabolic disorders that share the phenotype 
of hyperglycemia, with an increase incidence worldwide. The Indian subcontinent has a higher prevalence of DM 
than any other region in the world, and two to three times the reported prevalence in western countries. Recent 
surveys say that diabetes is affecting 10-16% of urban population. The disease Madhumeha described in Ayurveda 
bears close resemblance to Diabetes Mellitus. Objectives: To evaluate the effect of Saptachakra Choorna in the 
management of Madhumeha w.s.r. to type 2 DM and to compare it with drug taken in the control group. Materials 
and Method: In the present study, two groups were taken each comprising of 20 patients who fulfilled the 
diagnostic and inclusion criteria. Subjects of group A were administered Saptachakra Choorna 6gms twice daily and 
subjects of group B were administered tablet Metformin 500 mg one tablet twice daily, both before food and for a 
period of 45 days. Observation and Results: In the present study, majority of the symptoms showed clinically 
significant improvement by Saptachakra Choorna and metformin 500 mg, however it was not statistically 
significant. In the glycemic parameters like FBS, PPBS, FUS and PPUS within the group administered Saptachakra 
Choorna 6 gms only FBS and PPBS showed significant improvement where as parameters like FUS and PPUS there 
was no much improvement and within the group administered tablet Metformin 500 mg significant improvement in 
all the parameters were observed. On comparing the results between the two groups, the group administered 
tablet Metformin 500 mg showed a better result than the group administered Saptachakra Choorna. Conclusion: 
By seeing overall improvement and applying Chi Square Test, tablet Metformin 500 mg showed a better result than 
Saptachakra Choorna. 
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Anupa, Dadhini etc. and lifestyle such as Asyasukham 
Swapna Sukham.  
According to contemporary science along with oral 
hypoglycemic agents dietic and lifestyle modification 
is stressed upon D.M comprises a group of common 
metabolic disorders that share the phenotype of 
hyperglycemia, with an increase incidence worldwide. 
D.M will be a leading cause of morbidity and mortality 
for the foreseeable future. Hyperglycaemia is mainly 
caused by absolute or relative deficiency of insulin, 
this deficiency effects the metabolism of 
carbohydrates, protein, and fats further leading to 
significant disturbance of normal functioning of 
body.[1] 
Long standing metabolic degeneration is linked with 
functional and structural changes in various organs 
mainly effecting the eye, kidney, nervous system etc. 
Hence this condition needs to be given utmost 
importance from the beginning to avoid 
complications.  
Among the classification of OHA, Metformin comes 
under the biguanides and is currently the most 
commonly used oral agent to treat type 2 D.M. It is 
generally accepted as the first line treatment for this 
condition. The most frequent adverse effects of 
Metformin are gastrointestinal like anorexia, nausea, 
vomiting, abdomen discomfort, diarrhea and reduced 
absorption of vitamin B12.[2] This drug is meant to 
show hypoglycemic action but for the other adverse 
effects caused the patient needs to repeatedly see 
medical attention again which adds on to the burden 
of the patient. 
As Ayurvedic medications show a holistic approach 
there is a need to search a safe and effective 
medication for D.M over synthetic / chemical 
preparations. Saptachakra drug belongs to the family 
Celastraceae and is distributed across the world. 
Specially in India this plant is widely used and is a 
species which is widely known for its antidiabetic 
properties. Many studies regarding the roots are 
either chewed directly or taken in dried powdered 
form or as decoction are available. 
Prevalence of diabetes  
There will be at least 629 million people living with 
D.M by 2045. The proportion of people with type 2 
D.M is increasing in most countries. 79% of adults 
with Diabetes were living in low- and middle-income 
countries.[3] 
Recent surveys say that Diabetes is affecting 10-16% 
of urban population and 5-8 % of rural population.[4] 
Thus, this study is put forward focusing on evaluating 
the effect of Saptachakra Choorna in management of 
Madhumeha (type 2 D.M) 
AIMS AND OBJECTIVES 
1. To evaluate the effect of Saptachakra Choorna in 
the management of Madhumeha w.s.r to type 2 
D.M in the study sample. 
2. To evaluate the effect of tablet Metformin 500 mg 
in the management of Madhumeha w.s.r. to type 
2 D.M in the study sample. 
3. To compare the effect of Saptachakra Choorna 
and tablet Metformin 500 mg in the management 
of Madhumeha w.s.r to type 2 D.M in the study 
sample.  
MATERIALS AND METHODS 
For the present study patient were selected randomly 
from OPD, IPD and special camp conducted at Sri Sri 
College of Ayurvedic Science and Research Hospital, 
Bengaluru. 
Ethical Clearance and Consent 
The study was approved by the institutional ethical 
committee and signed informed consent was 
obtained from all the patients.  
Sampling Method and Research Design 
Total 40 patients were randomly selected and 
assigned into two groups of 20 each as Group A and B 
respectively.  
DIAGNOSTIC CRITERIA  
Subjective criteria 
Subjects presenting with Prabhuta Mutra, Avila Mutra 
and any of the classical signs and symptoms of 
Madhumeha such as Karapadadaha, 
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Karapadasuptata, Trishna,  Atisweda, Dourbalya were 
selected. 
Objective Criteria 
Subjects with F.B.S greater than 126 mg/dl less than 
160 mg/dl and P.P.B.S greater than 200 mg/dl less 
than 300 mg/dl were selected.   
Inclusion Criteria  
▪ The subjects irrespective of gender and of age 
group between 30 to 70 years. 
▪ Subjects presenting with classical signs and 
symptoms of Madhumeha such as Prabhuta 
Mutra, Avila Mutra and Karapadadaha, 
Karapadasuptata, Trishna, Atisweda, Dourbalya 
were selected. 
▪ Subjects with F.B.S greater than 126 mg/dl less 
than 160 mg/dl and P.P.B.S greater than 200 
mg/dl less than 300 mg/dl were selected. 
Exclusion Criteria 
▪ I.D.D.M patients. 
▪ Subjects under insulin therapy. 
▪ Gestational diabetes. 
▪ Type 2 D.M subjects under insulin therapy due to 
secondary failure. 
▪ Secondary D.M cases were excluded.  
Laboratory Investigation  
FBS, PPBS, FUS and PPUS were assessed on 0th day 
before treatment, 15th day, 30th day and 45th day.  
Intervention  
Group A: Saptachakra Choorna was administered  
with dosage of 6gms twice daily administered orally 
(before food) with warm water for 45 days.  
Group B: Metformin 500mg was administered with 
dosage of 1 tablet twice daily orally (before food) with 
water for 45 days. 
Assessment Criteria  
▪ Prabhutamutrara 
▪ Avilamutrata 
▪ Trishnadhikya (polydipsia) 






Assessment was done on 0th day, 15thday, 30th day and 
45th day. 
Statistical Analysis 
Statistical Analysis was done with - Unpaired T test, 
Paired T test for parametric data and Mann-Whitney 
U Test and Wilcoxon Sign Rank test for non-
parametric data.  
OBSERVATIONS 
In the present study maximum number of patients 
belonged to the age group 40-49 years, this shows 
more prevalence of D.M in middle and later decade of 
life. Risk of diabetes increases as age advances. (Table 
No 1). 
The incidence of female are more affected than 
males. This may be due to the demographic facts. 
(Table No 2) 
Incidence of Madhumeha in this study is most 
common in house wives followed by businessmen, 
this group contribute to a sedentary life style, lack of 
change of position for long which may have 
contributed to the disease process.(Table No 3). 
More urbanization and lifestyle changes leading to 
physical inactivity and consumption of diet rich in fat, 
sugar and calories along with mental stress 
contributes the disease process, which is true with a 
maximum patient belonging to middle class 
group.(Table no 4) 
Diseases including type 2 D.M, occur at lower BMI 
levels in Asian Indians compared to other ethnic 
groups,[5] here maximum patients have normal BMI 
index. (Table no 5) 
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Table 1: Showing the incidence of disease with 
relation to age. 
Age Group A Group B Total 
30-39 4  4 8 (20%) 
40-49 8 8 16 (40%) 
50-59 4 4 8 (20%) 
60-70 4 4 8 (20%) 
Table 2: Showing the incidence of disease with 
relation to gender. 
Gender Group A Group B Total  
Male 12 7 19 (47.5%) 
Female 8 13 21 (52.5%) 
Table 3: Showing the incidence of disease with 
relation to occupation. 
Occupation Group A Group B Total 
House wife 4 8 12 (30%) 
Businessmen   3 3 6 (15%) 
Cashier  2 2 4 (10%) 
Retired  1 2 3 (7.5%) 
Engineer  2 0 2 (5%) 
Others  8 5 13 (32.5%) 
Table 4: Showing the incidence of disease with 




Group A Group B Total 
Middle class 14 13 27 (67.5%) 
Lower 
middle class  
6 6 12 (30%) 
Upper 
middle class 
0 1 1 (2.5%) 
Table 5: Incidence of observation of patients 
according to their B.M.I 
B.M.I  Group A Group B Total% 
Normal index 13 17 30 (75%) 
Under weight 0 0 0 (0%) 
Over weight 5 3 8 (20%) 
Obesity 2 0 2 (5%) 
RESULTS 
In the current study it was observed that there was a 
reduction in symptoms like Prabutamutrata, 
Trishnadhikya, Karapadataladaha and Dourbalya in 
both the groups, except for Avilamutrata which 
remained the same in the group administered 
Saptachakra Choorna and reduced in group 
administered tablet Metformin 500 mg. There was 
improvement in the PPBS values in both the groups 
which was statistically significant (p value <0.01) and 
reduction in FBS, FUS and PPUS values but was not 
statistically significant (p value >0.05) before and after 
treatment.  
Over all clinically in the symptom of Trishnadhikya 
Saptachakra Choorna showed better results than 
tablet Metformin 500 mg, but statistically it was not 
significant (p value >0.005).  
In the other parameters like Prabhutamutrata, 
Avilamutrata, Karapadatala, Dourbalya group tablet 
Metformin 500 mg showed better results which was 
clinically significant but statistically not significant (p 
value>0.05).  
In the parameters like FBS, PPBS, FUS and PPUS group 
B (standard group) showed better results than group 
A (trial group) which was statistically significant (p 
value <0.01).(Table No 6 &7). 
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Table 6: Effect of medicine on chief complaints in the 
patients of Madhumeha in Group A 




0.65 0.10 0.008 
Avilamutrata  0.10 ±0.308 0.10 ±0.308 1.000 





0.30 ± 0.470 0.005 
Dourbalya 0.95 ± 
0.605 
0.25 ±0.00 0.001 
FBS  149.15 144.90 0.478 
PPBS 250.25 202.10 0.001 
FUS 0.05 0.10 0.330 
PPUS  0.18 0.28 0.408 
Table No: 7 Effect of medicine on chief complaints in 
the patients of madhumeha in Group B 
Symptoms  Mean Score  P value  
B.T A.T 
Prabhuta Mutrata 0.15 0.10 0.577 






















FBS  151.85 136.35 0.019 
PPBS 253.85 193.80 0.000 
FUS 0.05 0.00 0.330 
PPUS  0.70 0.13 0.005 
By assessing overall improvement through Chai 
Square Test Group B shows better result compared to 
Group A as shown in the table below (Table No 8). 
Table 8: Showing the Over All Improvement  
Symptoms Group UN ML MD MR 
Prabhuta 
Mutrata 
A 13 3 0 4 
B 18 0 0 2 
Avilamutrata A 18 0 0 2 
B 18 0 0 2 
Trishnadikya A 7 1 0 12 
B 7 3 0 10 
Kara Pada 
Tala Daha 
A 11 2 0 7 
B 13 0 0 7 
Dourbalya A 8 0 0 12 
B 5 0 0 15 
UN=unchanged, ML= mild, MD= moderate, MR= marked 
Relief. A=Group A, B= Group B. 
On the overall assessment when done by simple 
percentile calculation the group administered tablet 
Metformin 500 mg showed better results than the 
group administered Saptachakra Choorna. 
DISCUSSION  
Prabutamutrata 
In this study, when we compare the effect of 
medicines given in group A and B, there was no 
difference and it is statistically not significant with p 
value 1.00. This shows that both group A and group B 
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show similar effect on the symptom of 
prabutamutrata.  
The gradation results within each group are tabulated 
below (Table No 9&10). 
Saptachakra Choorna has the properties of 
mutrasangrahaniya[6] which may be the reason for 
reduction in symptoms of Prabutamutrata. 
The most common cause of polyuria is uncontrolled 
D.M, which causes osmotic diuresis, when glucose 
level is high that glucose is excreted in urine, tablet 
Metformin has hypoglycaemic effect[7] which could be 
the reason for reduction in the symptom of 
Prabutamutrata.   
Avilamutrata 
When we compared the effect of medicines given in 
group A and B, group B showed better results than 
group A, but it is statistically not significant with p 
value 0.602 
The gradation results within each group are tabulated 
below (Table No 9&10). The reduction in Avilamutrata 
may be due to improved blood glucose levels brought 
about by the antidiabetic action of the drug which 
further helps kidneys to filter urine appropriately. 
Trishnadhikya 
Group A showed better results than group B but it is 
statistically not significant with p value 0.289 on the 
symptom of Trishnadhikya. 
Trishnadhikya is mainly caused by the involvement of 
Pitta and Vata, the medicine administered in group A 
has a Karma of Pitta Shamaka.[6] This might have 
reduced this symptom. The gradation results within 
each group are tabulated below. (Table No 9&10) 
Kara Pada Tala Daha 
Group B showed better results than group A but it is 
statistically not significant with p value 0.602. 
The Dāha in patients of Madhumeha may be due to 
vitiation of Vāta and Pitta. Saptachakra drug has a 
property of Pitta Shamaka and the root bark contains 
1,3 diketones as one of its chemical composition.[8] 
Which directly reduces symptoms of neuropathy 
along with the action of reduced glucose level. 
Kara Pada Tala Daha may have indirectly reduced by 
a good glycemic control which prevented further 
damage to the nerves. The gradation results within 
each group are tabulated below. (Table No 9&10) 
Dourbalyata 
Group B showed better results than group A but it is 
statistically not significant with p value 0.583. 
Metformin enhances the insulin - mediated glucose 
uptake and disposal in skeletal muscles and fat thus 
overcoming insulin resistance and further helping the 
cell to utilize glucose to produce energy therefore 
reducing this symptom.The gradation results within 
each group are tabulated below. (Table No 9&10) 
FBS 
Group B showed better results than group A and it is 
statistically significant with p value 0.041. The value 
range results within each group are tabulated below 
(Table No 11 & 12). Saptachakra Choorna is indicated 
as Madhumehahara[6] hence showing its action. 
Metformin suppresses hepatic gluconeogenesis and 
glucose output from liver, this may be the reason for 
reducing the blood glucose level. 
PPBS 
Group B showed better results than group A and it is 
statistically significant with p value 0.021. The value 
range results within each group are tabulated 
below.(Table No 11& 12) 
FUS   
Group B showed better results than group A and it is 
statistically highly significant with p value 0.002. 
Saptachakra Choorna has action on 
Muratravahasamsthana along with Madhumehahara 
property.[6] Metformin suppresses gluconeogenesis 
and glycose out put from liver which reduces the 
glucose level circulating in blood which may be the 
reason for reduction in FUS. The value range results 
within each group are tabulated below.(Table No 11& 
12) 
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PPUS 
Group B showed better results than group A and it is 
statistically highly significant with p value 0.021. 
Metformin has a property to retards glucose 
absorption from the intestine which may be the 
reason for glycemic control hence leading to 
reduction in PPUS.  
The value range results within each group are 
tabulated below.(Table No 11 & 12) 
Table 9: Showing the results of interventions on 
Symptoms in Group A 



















11 5 4 0 18 2 0 0 
Avilamutrat
a  
18 2 0 0 18 2 0 0 
Trishnadiky
a  
6 10 4 0 16 4 0 0 
Kara Pada 
Tala Daha 
9 5 6 0 14 6 0 0 
Dourbalya 4 13 3 0 16 3 1 0 
GR - Grade , BT - Before Treatment, AT - After Treatment, C.F - 
Clinical Features. 
Table 10:  Showing the results of interventions on 
Symptoms in Group B 



















17 3 0 0 18 2 0 0 
Avilamutrata  18 2 0 0 20 0 0 0 
Trishnadikya  0 19 1 0 12 8 0 0 
Kara Pada 
Tala Daha 
11 7 2 0 16 4 0 0 
Dourbalya 3 15 2 0 18 2 0 0 
GR - Grade , BT - Before Treatment, AT - After Treatment, C.F - 
Clinical Features. 
 
Table 11:  Showing the results of interventions on Symptoms in Group A 
C.F B.T 45th Day (A.T) 
FBS 
Range 


































0 5 7 1 7 0 10 3 3 2 1 1 
FUS 
Range  









Nil  P 
(0.5%) 
P (1%) P 
(1.5%) 
P (2%) 
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 19 0 1 0 0 18 0 2 0 0 
PPUS 
Range  









Nil  P 
(0.5%) 
P (1%) P 
(1.5%) 
P (2%) 
17 2 0 1 0 15 1 3 0 1 
Table 12:  Showing the results of interventions on Symptoms in Group B 
C.F B.T 45th Day (A.T) 
FBS 
Range 











0 5 6 9 0 4 7 4 3 2 
PPBS 
Range  

















0 6 2 4 8 0 8 9 3 0 0 0 
FUS 
Range  








Nil  P (0.5%) P (1%) P (1.5%) P (2%) 
19 0 1 0 0 20 0 0 0 0 
PPUS 
Range  








Nil  P (0.5%) P (1%) P (1.5%) P (2%) 
8 3 3 5 1 16 3 1 0 0 
BT- Before Treatment, AT- After Treatment, C.F- Clinical Features, P- present  
 
CONCLUSION 
Madhumeha has been discussed in Prameha Roga as 
one among the Vataja Prameha. Further Vataja 
Prameha has two types, among them Avaranajanya 
Madhumeha can be corelated to type 2 D.M. An effort 
was made to evaluate the effect of Saptachakra 
Churna which has the property of Madhumehahara 
and was compared with the effect of tablet 
Metformin 500 mg which is the most commonly used 
OHA to treat type 2 DM. It was observed that most of 
the patient’s nature of work was prolonged sitting and 
standing, which is also mentioned as one of the 
Nidana leading to Madhumeha. 
 
There was a reduction in symptoms like 
Prabutamutrata, Trishnadhikya, Karapadataladaha 
and Dourbalya in both the groups before treatment 
and after treatment, except for Avilamutrata which 
remained the same in group A and reduced in group 
B. There was improvement in the PPBS values in both 
the groups which was statistically significant and 
reduction in FBS, FUS and PPUS values but was not 
statistically significant BT and AT. Over all clinically in 
the symptom of Trishnadhikya group A showed better 
results than group B, but statistically it was not 
significant. In the other parameters like 
Prabhutamutrata, Avilamutrata, Karapadatala, 
Dourbalya group B showed better results which was 
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clinically significant but statistically non-significant. In 
the parameters like FBS, PPBS, FUS and PPUS group B 
showed better results than group A which was 
statistically significant. In the overall assessment 
group B showed better results than group A. 
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